摘要
Abstract
Chimeric antigen receptor T cell(CAR-T)therapy,which involves genetically engineering T cells to specifically recognize and efficiently eliminate target cells,has achieved groundbreaking success in treating hematological malignancies such as B-cell lymphoma and leukemia.Driven by its unique mechanism of action,research into extending its applications to other disease areas is actively underway.In particular,CAR-T therapy has shown significant potential in treating autoimmune diseases(AIDs),attracting considerable attention.Current conventional treatments for AIDs,including glucocorticoids,immunosuppressants,and biologics,are often associated with limitations such as limited efficacy,short duration of remission,and long-term toxicity.In contrast,CAR-T therapy has emerged as a highly promising treatment strategy for AIDs,owing to its advantages of precise targeting and the capacity to induce sustained,drug-free remission.This article reviews recent preclinical and clinical advances in CAR-T therapy for various AIDs,demonstrating its feasibility in eradicating pathogenic B cells and reestablishing immune tolerance.It also examines the major challenges confronting this treatment approach,including adverse effects,limited persistence,and treatment resistance in some patients.Furthermore,strategies to address these challenges are discussed,focusing on the optimization of the chimeric antigen receptor(CAR)structure,the exploration of novel specific targets,and the development of universal CAR-T products.Finally,future research directions are outlined,with the aim of providing a rational foundation for the further development and refinement of CAR-T therapy for AIDs.关键词
嵌合抗原受体T细胞/细胞免疫疗法/自身免疫性疾病Key words
chimeric antigen receptor T cell/cellular immunotherapy/autoimmune diseases分类
医药卫生
